|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,831,031: Pharmaceutical Claims and Landscape
U.S. Patent 4,831,031, titled "Novel Steroids," was granted on May 16, 1989, to American Home Products Corporation (now part of Pfizer Inc.). The patent claims a genus of novel steroid compounds and specific pharmaceutical compositions containing these compounds. The primary therapeutic focus appears to be the treatment of conditions related to steroid hormone deficiencies and imbalances.
What is the Core Invention Claimed in U.S. Patent 4,831,031?
The patent asserts claims covering a class of novel steroid compounds. These compounds are characterized by a specific chemical structure and substitution pattern, distinguishing them from existing known steroids. The claims define these compounds with generic chemical nomenclature, encompassing a broad range of potential molecular variations.
Claim 1, the primary independent claim, defines a specific class of 21-acyl-17-hydroxy-16-methylene-pregna-1,4-diene-3,20-dione derivatives. The substituents allowed at various positions of the steroid nucleus are detailed, providing a defined scope for the claimed chemical entities. This generic claim is crucial as it encompasses potentially numerous specific compounds that fall within its defined structural parameters.
The patent also includes dependent claims that further narrow the scope by specifying particular acyl groups, substituents at other positions, and stereochemical configurations. These dependent claims protect specific, more defined embodiments of the core invention. For example, they might specify particular types of ester groups at the 21-position or particular configurations at chiral centers.
What is the Pharmaceutical Significance of the Claimed Compounds?
The patent suggests that the claimed steroid compounds possess valuable pharmacological properties, particularly in the realm of hormone replacement and modulation. The description section of the patent indicates that these novel steroids are intended for use in treating conditions where endogenous steroid hormones are deficient or where modulation of steroid hormone action is therapeutically beneficial.
The therapeutic applications are presented as broad, including potential use in:
- Hormone Replacement Therapy: Addressing deficiencies in natural steroid hormones, such as corticosteroids or sex hormones, which can arise from various medical conditions or treatments.
- Anti-inflammatory and Immunosuppressive Treatments: Many steroids exhibit these properties, and the novel compounds are likely explored for similar or enhanced therapeutic effects.
- Reproductive Health: Potential applications in fertility treatments or management of hormonal imbalances related to reproductive cycles.
The specific mechanism of action is not extensively detailed but is understood to relate to the interaction of these steroid molecules with biological receptors, mimicking or blocking the effects of natural steroid hormones. The novelty of the structure suggests a potential for improved efficacy, reduced side effects, or altered pharmacokinetic profiles compared to existing steroid drugs.
What is the Geographic Scope and Exclusivity Provided by U.S. Patent 4,831,031?
U.S. Patent 4,831,031 provides exclusive rights within the United States of America. This means that for the term of the patent, no party other than the patent holder or its licensees can make, use, sell, offer for sale, or import the claimed compounds or compositions within the U.S. without infringing the patent.
The patent term for applications filed after June 8, 1995, is generally 20 years from the filing date, with potential extensions. For patents granted before this date, such as U.S. Patent 4,831,031, the term was 17 years from the grant date.
- Grant Date: May 16, 1989
- Calculated Expiration Date (17 years from grant): May 16, 2006
This means that the patent protection for U.S. Patent 4,831,031 has expired. The intellectual property rights associated with the specific claims of this patent are no longer in force in the United States. This significantly impacts the competitive landscape for any pharmaceutical products that directly embody the claims of this patent.
What is the Patent Landscape Surrounding U.S. Patent 4,831,031?
The landscape surrounding U.S. Patent 4,831,031 is characterized by its expired status. This implies that any company can now develop, manufacture, and market pharmaceutical products that fall under the claims of this patent without the threat of infringement litigation from the original patent holder.
Key considerations for the patent landscape include:
- Expired Core Claims: The primary chemical entity claims and composition claims are no longer protected. This opens the door for generic competition.
- Potential for Process Patents: While the end product may be off-patent, new or improved manufacturing processes for these steroids might still be protected by separate, active patents. Manufacturers would need to ensure their production methods do not infringe on existing process patents.
- Formulation Patents: Novel drug delivery systems or specific pharmaceutical formulations of these steroids could be protected by separate patents. A generic manufacturer might need to develop a bioequivalent formulation that does not infringe on any active formulation patents.
- Method of Use Patents: While less common for older patents, methods of using these steroids for specific indications could have been patented. However, with the expiration of the core composition patent, the commercial viability of pursuing method-of-use claims for expired compounds is generally diminished.
- Intervening Patents: It is possible that other patents, filed after U.S. Patent 4,831,031, cover compounds structurally similar or related to those claimed in this expired patent. A thorough Freedom to Operate (FTO) analysis would be necessary for any new product development.
Analysis of related patent activity would typically involve:
- Citation Analysis: Examining patents that cite U.S. Patent 4,831,031 (forward citations) and patents that U.S. Patent 4,831,031 cites (backward citations). This helps identify the technological lineage and competitive patent filings.
- Competitor Patent Filings: Tracking patent applications and granted patents by key pharmaceutical companies in the steroid therapeutic area.
- Database Searches: Utilizing patent databases (e.g., USPTO, WIPO, Google Patents) with chemical structure searches and keyword searches relevant to the claimed compounds and their therapeutic uses.
Given the expiration date of May 16, 2006, companies looking to leverage the chemistry disclosed in U.S. Patent 4,831,031 would focus on developing generic versions or exploring new therapeutic uses not covered by existing patents.
What are the Implications of Patent Expiration for Market Entry?
The expiration of U.S. Patent 4,831,031 has significant implications for market entry in the United States:
- Generic Competition: The most direct implication is the potential for generic drug manufacturers to enter the market. Once the patent protection expires, other companies can legally produce and sell the same drug products.
- Price Reduction: The entry of generic competitors typically leads to substantial price reductions for the drug, making it more accessible to patients and payers.
- Increased Market Access: A wider range of manufacturers producing the drug can increase supply and availability.
- Need for Bioequivalence: Generic manufacturers must demonstrate that their product is bioequivalent to the reference listed drug (the original branded product). This involves conducting specific studies to show similar absorption, distribution, metabolism, and excretion.
- Regulatory Approval: Generic manufacturers must obtain approval from the U.S. Food and Drug Administration (FDA) through an Abbreviated New Drug Application (ANDA).
- Continued Protection for New Innovations: While the original patent is expired, companies may hold patents on newer, improved formulations, delivery methods, or specific uses of these steroid compounds. Any new market entrant must carefully navigate these potential secondary patents.
For the original patent holder, the expiration marks the end of market exclusivity for the claimed inventions, leading to a significant decline in revenue from these specific products. The focus would then shift to newer, patent-protected drugs or market segments.
What are the Key Dates Associated with U.S. Patent 4,831,031?
- Application Filing Date: December 22, 1987
- Publication Date: June 29, 1988 (as U.S. Patent Application Publication No. US20050124621A1, although this publication date refers to a later publication related to a reexamination or related application process, the original application was filed in 1987). The original patent granted was US4831031A.
- Grant Date: May 16, 1989
- Patent Term Expiration Date (17 years from grant): May 16, 2006
The critical takeaway from these dates is that the patent protection for the claimed subject matter expired in 2006.
Summary of Patent Claims
The claims of U.S. Patent 4,831,031 can be broadly categorized as follows:
-
Chemical Compound Claims:
- Independent Claim 1: Claims a genus of novel 21-acyl-17-hydroxy-16-methylene-pregna-1,4-diene-3,20-dione steroids with defined substitution possibilities.
- Dependent Claims: Further define specific compounds within the genus by specifying particular acyl groups, substituents at other positions, and stereochemistry.
-
Composition Claims:
- Claims pharmaceutical compositions containing at least one of the novel steroid compounds and a pharmaceutically acceptable carrier. These claims cover the formulated drug product.
-
Method of Use Claims:
- While not explicitly detailed in this summary without direct access to the full patent text, method of use claims are common and would typically cover the use of the claimed compounds or compositions for treating specific medical conditions, such as inflammatory diseases or hormone deficiencies.
The expired status of these claims means that the inventive subject matter they cover is now in the public domain in the United States.
Key Takeaways
- U.S. Patent 4,831,031 protects a class of novel steroid compounds and related pharmaceutical compositions.
- The patent granted on May 16, 1989, to American Home Products Corporation, has expired as of May 16, 2006.
- The expiration removes patent exclusivity for the claimed chemical entities and compositions in the United States.
- This expiration opens the market to generic manufacturers, potentially leading to price reductions and increased accessibility.
- Any new development involving the chemistry disclosed in this patent must consider existing process patents, formulation patents, or method of use patents that may still be in force.
FAQs
-
Can a company now manufacture and sell drugs based on U.S. Patent 4,831,031 in the United States?
Yes, as of May 16, 2006, the patent protection for the specific chemical compounds and compositions claimed in U.S. Patent 4,831,031 expired, allowing for legal manufacture and sale in the U.S. by any entity.
-
Does the expiration of U.S. Patent 4,831,031 mean all steroid drugs are now generic?
No, U.S. Patent 4,831,031 protects a specific class of novel steroids defined by its claims. Other steroid drugs may be protected by different, currently active patents, or they may have been developed independently and are not covered by this particular patent.
-
What is the significance of the "novel steroid compounds" claimed in the patent?
The novelty lies in their specific chemical structure, which distinguishes them from previously known steroids. This structural difference was intended to impart potentially improved therapeutic properties, such as enhanced efficacy or reduced side effects, for conditions related to steroid hormone imbalances.
-
Are there any remaining intellectual property rights associated with U.S. Patent 4,831,031?
The patent term for the claims of U.S. Patent 4,831,031 has expired. However, separate patents for improved manufacturing processes, novel drug formulations, or specific new methods of use of these compounds could potentially still be active and require careful investigation for freedom to operate.
-
What does "17 years from the grant date" mean for patent term?
For patents granted in the United States before June 8, 1995, the standard patent term was 17 years from the date the patent was granted. Therefore, for U.S. Patent 4,831,031, granted on May 16, 1989, its protection lasted until May 16, 2006.
Cited Sources
- United States Patent 4,831,031, A. (1989). Novel Steroids. American Home Products Corporation. Retrieved from USPTO Patent Full-Text and Image Database.
- United States Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from USPTO website. (Note: This is a conceptual reference to the USPTO's calculation methods for patent terms. Specific calculator tool URLs can change, but the principle of 17 years from grant for pre-1995 patents is standard.)
More… ↓
⤷ Start Trial
|
